Want to see AIRS full AI Analyst Report?
AIRS Stock Chart & Stats
$3.57
>-$0.01(-0.17%)
At close: 4:00 PM EST
$3.57
>-$0.01(-0.17%)
Day’s Range― - ―
52-Week Range$1.51 - $12.00
Previous CloseN/A
Volume69.34K
Average Volume (3M)1.05M
Market Cap
$313.93M
Enterprise Value$252.50
Total Cash (Recent Filing)$16.69M
Total Debt (Recent Filing)$71.02M
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Aug 07, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding70,545,685
10 Day Avg. Volume629,231
30 Day Avg. Volume1,053,493
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.36
Price to Sales (P/S)0.79
P/FCF Ratio172.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.50Price Target Upside26.05% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$153.35M
Bulls Say, Bears Say
Bulls Say
Proprietary Procedure & Vertically Integrated ModelAirSculpt’s proprietary minimally invasive procedure combined with company-owned clinics creates durable unit economics: owning operations lets the firm capture procedure revenue, standardize patient experience, and scale per-clinic margins, supporting sustainable revenue per location and repeatable expansion.
Improved Cash GenerationA meaningful improvement to positive operating and free cash flow strengthens financial flexibility over the medium term. Better cash conversion reduces reliance on external capital, supports reinvestment in center openings or marketing, and lowers execution risk for strategic investments.
Reduced Leverage And De-risked Balance SheetDeclining debt-to-equity and a stronger equity base materially lower balance-sheet risk. This creates lasting optionality to pursue growth or absorb elective-procedure demand volatility, and reduces refinancing pressure, improving resilience across 2–6 month planning horizons.
Bears Say
Stagnant Revenue TrendFlat trailing-twelve-month revenue indicates limited organic demand expansion or constrained clinic utilization. For an elective-procedure business, persistent top-line stagnation undermines operating leverage and makes achieving durable margin improvement and scale economics more difficult without clear expansion or marketing success.
Ongoing Net Losses And Negative Operating ProfitSustained net losses and negative operating profit limit retained-earnings accumulation and return generation. Over the medium term this constrains reinvestment, increases reliance on cash flow improvements or external capital, and weakens the company’s ability to deliver consistent shareholder returns.
Operating Cash Flow Modest Vs. Debt BurdenAlthough cash generation improved, operating cash remains modest compared with total debt, leaving limited headroom for aggressive expansion or debt paydown. If cash flow stalls, the company may face financing constraints or higher borrowing costs, raising structural funding risk over the medium term.
Airsculpt Technologies News
AIRS FAQ
What was Airsculpt Technologies, Inc.’s price range in the past 12 months?
Airsculpt Technologies, Inc. lowest stock price was $1.51 and its highest was $12.00 in the past 12 months.
What is Airsculpt Technologies, Inc.’s market cap?
Airsculpt Technologies, Inc.’s market cap is $313.93M.
When is Airsculpt Technologies, Inc.’s upcoming earnings report date?
Airsculpt Technologies, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 19 days.
How were Airsculpt Technologies, Inc.’s earnings last quarter?
Airsculpt Technologies, Inc. released its earnings results on May 08, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Airsculpt Technologies, Inc. overvalued?
According to Wall Street analysts Airsculpt Technologies, Inc.’s price is currently Undervalued.
Does Airsculpt Technologies, Inc. pay dividends?
Airsculpt Technologies, Inc. pays a Notavailable dividend of $0.41 which represents an annual dividend yield of N/A. See more information on Airsculpt Technologies, Inc. dividends here
What is Airsculpt Technologies, Inc.’s EPS estimate?
Airsculpt Technologies, Inc.’s EPS estimate is 0.02.
How many shares outstanding does Airsculpt Technologies, Inc. have?
Airsculpt Technologies, Inc. has 70,545,685 shares outstanding.
What happened to Airsculpt Technologies, Inc.’s price movement after its last earnings report?
Airsculpt Technologies, Inc. reported an EPS of -$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 11.561%.
Which hedge fund is a major shareholder of Airsculpt Technologies, Inc.?
Currently, no hedge funds are holding shares in AIRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Airsculpt Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.50 (26.05% Upside)
$4.50 (26.05% Upside)
Blogger Sentiment
Neutral
AIRS Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 573.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $101.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.81%
12-Months-Change
Fundamentals
Return on Equity
-12.42%
Trailing 12-Months
Asset Growth
-5.54%
Trailing 12-Months
Company Description
Airsculpt Technologies, Inc.
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States, Canada, and the United Kingdom. The company offers AirSculpt, a body contouring treatment that removes fat and tightens skin while sculpting targeted areas of the body in a minimally invasive procedure. It also provides AirSculpt+, a procedure that permanently removes fat and tightens the skin with unparalleled precision and finesse; and AirSculpt Smooth, an advanced cellulite removal tool. In addition, it provides fat removal procedures across treatment areas, such as the stomach, back, and buttocks; and fat transfer procedures that transfers the patient’s own fat cells to enhance the buttocks, breasts, hips, aging hands, or other areas. Further, the company’s body contouring procedures include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. Additionally, it operates various centers. AirSculpt Technologies, Inc. was founded in 2012 and is headquartered in Miami Beach, Florida.
AIRS Stock 12 Month Forecast
Average Price Target
$4.50
▲(26.05% Upside)
Technical Analysis
AMN Healthcare Services
―
Community Health
―
Cross Country Healthcare
―
Healthcare Services
―
National Healthcare
―
Ownership Overview
48.20% Insiders
1.28% Mutual Funds
46.97% Other Institutional Investors
1.74% Public Companies and
Individual Investors